Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
CONCLUSION:  Our results suggested that the combination of the HDAC3 and HDAC9 genes with a history of diabetes mellitus could exacerbate the deterioration of atherosclerosis, thereby increasing the risk of IS. Further studies are warranted to explore our results in other populations. PMID: 32961570 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 22, 2020 Category: Hematology Authors: Chiou HY, Bai CH, Lien LM, Hu CJ, Jeng JS, Tang SC, Lin HJ, Hsieh YC Tags: Thromb Haemost Source Type: research

Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation.
In conclusion, ibrutinib suppresses early megakaryopoiesis, as evidenced by inhibition of MK progenitor cell proliferation and CFU-MK formation. Ibrutinib enhances MK differentiation, ploidy, and proplatelet formation, while it impairs integrin αIIbβ3 outside-in signaling. PMID: 32961571 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 22, 2020 Category: Hematology Authors: Huang J, Huang S, Ma Z, Lin X, Li X, Huang X, Wang J, Ye W, Li Y, He D, Yang M, Pan J, Ling Q, Li F, Mao S, Wang H, Wang Y, Jin J Tags: Thromb Haemost Source Type: research

Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19.
Abstract The prospective observational cohort study COMPASS-COVID-19 aimed to develop a risk assessment model for early identification of hospitalized COVID-19 patients at risk for worsening disease. Patients with confirmed COVID-19 (n = 430) hospitalized between March 18 and April 21, 2020 were divided in derivation (n = 310) and validation (n = 120) cohorts. Two groups became evident: (1) good prognosis group (G-group) with patients hospitalized at the conventional COVID-19 ward and (2) Worsening disease group (W-group) with patients admitted to the intensive care unit (...
Source: Thrombosis and Haemostasis - September 22, 2020 Category: Hematology Authors: Gerotziafas GT, Sergentanis TN, Voiriot G, Lassel L, Papageorgiou C, Elabbadi A, Turpin M, Vandreden P, Papageorgiou L, Psaltopoulou T, Terpos E, Dimopoulos MA, Parrot A, Cadranel J, Pialoux G, Fartoukh M, Elalamy I Tags: Thromb Haemost Source Type: research

Intrathrombus Fibrin Attenuates Spatial Sorting of Phosphatidylserine Exposing Platelets during Clotting Under Flow.
CONCLUSION:  PS sorting correlated with clot contraction, as previously reported. However, fibrin inversely correlated with both percent contraction and PS sorting. Fibrin attenuated clot contraction and PS sorting relative to clots without fibrin. PMID: 32961573 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 22, 2020 Category: Hematology Authors: Trigani KT, Diamond SL Tags: Thromb Haemost Source Type: research

COVID-19 patients exhibit reduced procoagulant platelet responses.
CONCLUSIONS: We observed that platelets isolated from COVID-19 patients had a reduced ability to become procoagulant compared to those from matched healthy donors, as evidenced by reduced mitochondrial depolarization and phosphatidylserine exposure following dual stimulation with thrombin and convulxin. To understand what impact reduced procoagulant platelet responses might have in vivo, we subjected mice with a platelet-specific deletion of cyclophilin D, which are deficient in procoagulant platelet formation, to a model of pulmonary microvascular thrombosis. Mice with platelets lacking cyclophilin D died significantly fa...
Source: Thrombosis and Haemostasis - September 18, 2020 Category: Hematology Authors: Denorme F, Manne BK, Portier I, Petrey AC, Middleton E, Kile BT, Rondina MT, Campbell RA Tags: J Thromb Haemost Source Type: research

Letters to the Editors: letter in response to Bhogal and colleagues.
Abstract We thank Bhogal and colleagues for their positive comments on our manuscript and their perspective on VWF being a potential driver of COVID-19 microvascular thrombosis rather than a mere biomarker of endotheliopathy. It is well-known that VWF promotes neutrophil recruitment to endothelial surfaces under low-shear conditions and supports neutrophil extravasation towards inflamed tissues1 . This pro-inflammatory role of VWF involves two distinct pathways: (1) a direct interaction of neutrophil receptors (PSGL1 and β2-integrins) with VWF, and (2) an indirect interaction in which neutrophils adhere to VW...
Source: Thrombosis and Haemostasis - September 18, 2020 Category: Hematology Authors: Susen S, Rauch A, Lenting P Tags: J Thromb Haemost Source Type: research

Defibrotide in the COVID-19 coagulopathy: what is the timing?
asa G Abstract We appreciate the insightful comments by Richardson E et al. [1] about our letter [2], which contributed to better explore the fundamental concepts of our study by providing important, additional information for reflection. The identification of additional mechanisms involved in the endothelial damage as that described by Richardson et al. [1] mediated by the p38 MAPK pathway, which is upregulated as a result of the binding of SARSCoV2 on ACE2 receptors on the surface of endothelial cells and, in turn, activates the transcription of the proinflammatory cytokines. PMID: 32945111 [PubMed - as sup...
Source: Thrombosis and Haemostasis - September 18, 2020 Category: Hematology Authors: Macciò A, Madeddu C, Caocci G, Oppi S, La Nasa G Tags: J Thromb Haemost Source Type: research

Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?
PMID: 32942314 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 17, 2020 Category: Hematology Authors: Pandey AK, Eikelboom JW Tags: Thromb Haemost Source Type: research

Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Abstract Nonvitamin K oral anticoagulants (NOACs) or direct oral anticoagulants comprise inhibitors of factor Xa (rivaroxaban, apixaban, edoxaban) or factor IIa (dabigatran). Both classes efficiently interfere with the final or penultimate step of the coagulation cascade and showed superior net clinical benefit compared with vitamin K antagonists for prevention of thromboembolic events in patients with AF and for prevention and therapy of deep vein thrombosis and pulmonary embolism. None the less, accumulating data suggested, that there may be differences regarding the frequency of atherothrombotic cardiovascular ...
Source: Thrombosis and Haemostasis - September 17, 2020 Category: Hematology Authors: Polzin A, Dannenberg L, Thienel M, Orban M, Wolff G, Hohlfeld T, Zeus T, Kelm M, Petzold T Tags: Thromb Haemost Source Type: research

Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke.
CONCLUSIONS: In our study of mild to moderate ischemic stroke patients, high activity levels of FXI and FVIII but not FXII were associated with worse vascular outcomes in the three-year period after first ischemic stroke. PMID: 32935900 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 16, 2020 Category: Hematology Authors: Rohmann JL, Huo S, Sperber PS, Piper SK, Rosendaal FR, Heuschmann PU, Endres M, Liman TG, Siegerink B Tags: J Thromb Haemost Source Type: research

Diverse Activities of von Willebrand Factor in Traumatic Brain Injury and Associated Coagulopathy.
Abstract Traumatic brain injury (TBI) is a leading cause of death and disability. Patients with isolated TBI lose a limited amount of blood to primary injury, but they often develop secondary coagulopathy, resulting in delayed or recurrent intracranial and intracerebral hematoma. TBI-induced coagulopathy is closely associated with poor outcomes for these patients, including death. This secondary coagulopathy is consumptive in nature, involving not only brain-derived molecules, coagulation factors, and platelets, but also endothelial cells in a complex process now called endotheliopathy. A key question is how a loc...
Source: Thrombosis and Haemostasis - September 15, 2020 Category: Hematology Authors: Xu X, Kozar R, Zhang J, Dong JF Tags: J Thromb Haemost Source Type: research

Coagulation Characterization of Prothrombin 20209C   >  T Variant: About 27 New Cases.
Coagulation Characterization of Prothrombin 20209C > T Variant: About 27 New Cases. Thromb Haemost. 2020 Sep 15;: Authors: Jourdi G, Lobies S, Kosmider O, Duchemin J, Audureau E, Conard J, Mazoyer E, Horellou MH, Gouin-Thibault I, Flaujac C, Fontenay M PMID: 32932543 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 15, 2020 Category: Hematology Authors: Jourdi G, Lobies S, Kosmider O, Duchemin J, Audureau E, Conard J, Mazoyer E, Horellou MH, Gouin-Thibault I, Flaujac C, Fontenay M Tags: Thromb Haemost Source Type: research

von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
DISCUSSION:  VWF:Ag expression, a marker of endothelial ± platelet activation, is enhanced in recently symptomatic versus asymptomatic carotid stenosis patients, including in MES-ve patients, and decreases with ADAMTS13 activity over time following atherosclerotic TIA/ischemic stroke. PMID: 32932544 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 15, 2020 Category: Hematology Authors: Murphy SJX, Lim ST, Hickey F, Kinsella JA, Smith DR, Tierney S, Egan B, Feeley TM, Murphy SM, Collins DR, Coughlan T, O'Neill D, Harbison JA, Madhavan P, O'Neill SM, Colgan MP, O'Donnell JS, O'Sullivan JM, Hamilton G, McCabe DJH Tags: Thromb Haemost Source Type: research

Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
CONCLUSION: These new results should contribute to improve the safety of these targeted therapies. PMID: 32926549 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 14, 2020 Category: Hematology Authors: Series J, Ribes A, Garcia C, Souleyreau P, Bauters A, Morschhauser F, Jürgensmeier JM, Sié P, Ysebaert L, Payrastre B Tags: J Thromb Haemost Source Type: research

Pathological Features of Ruptured Coronary Plaque and Thrombus Interfaces: Fibrin and von Willebrand Factor as Platelet Scaffolds on Rupture Sites.
Abstract Arterial thrombus formation is thought to be initiated by platelet adhesion to the subendothelial matrix, but ruptured atherosclerotic plaques are characterized by substantial reduction of matrix proteins compared with stable plaques. Intraplaque erythrocytes and/or fibrin have been reported in high-risk coronary plaques. The aims of the current study were to identify factors that provide scaffolds for platelets at the sites of ruptured coronary plaques and investigate depositions of iron and bilirubin as hemoglobin catabolites in the ruptured plaques. Histological characteristics of plaque components and...
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Yamashita A, Nishihira K, Gi T, Maekawa K, Hatakeyama K, Horiuchi S, Wada K, Shibata Y, Asada Y Tags: Thromb Haemost Source Type: research

Tissue Factor-Independent Coagulation Correlates with Clinical Phenotype in Factor XI Deficiency and Replacement Therapy.
CONCLUSION:  TF-independent coagulation parameters assessed by TD have the potential to identify the clinical phenotype in FXI-deficient patients and to monitor FXI replacement therapy. PMID: 32920807 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Bertaggia Calderara D, Zermatten MG, Aliotta A, Batista Mesquita Sauvage AP, Carle V, Heinis C, Alberio L Tags: Thromb Haemost Source Type: research

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
Abstract BACKGROUND:  The effects of anticoagulants at extremes of body weight (BW) are not well described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics and clinical outcomes in patients randomized to warfarin, higher dose edoxaban (HDER), and lower dose edoxaban (LDER) regimens at extremes of BW in ENGAGE AF-TIMI 48. METHODS AND RESULTS:  We analyzed three BW groups: low BW (LBW: 95th percentile, ≥120 kg, N = 1,093). In the warfarin arm, LBW patients had higher rates of stroke/systemic embolism (SSE: 6.5 vs. 4.7 in MBW vs. 1.6% in HBW, P trend 
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP Tags: Thromb Haemost Source Type: research

Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency.
CONCLUSION:  Antithrombin p.Thr147Ala, responsible for antithrombin type II heparin binding site deficiency, is the first founder mutation reported in people of African ancestry. This study further emphasizes the limitations of commercial methods to diagnose this specific subtype. PMID: 32920809 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Orlando C, de la Morena-Barrio B, Pareyn I, Vanhoorelbeke K, Martínez-Martínez I, Vicente V, Corral J, Jochmans K, de la Morena-Barrio ME Tags: Thromb Haemost Source Type: research

The Multiple Faces of Heparin: Opportunities in COVID-19 Infection and Beyond.
PMID: 32920810 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Drouet L, Harenberg J, Torri G Tags: Thromb Haemost Source Type: research

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.
ova R, Cosmi B, De Marchi S, Dimakakos E, Dimopoulos MA, Dimitrov G, Durand-Zaleski I, Edmonds M, El Nazar EA, Erer D, Esponda OL, Gresele P, Gschwandtner M, Gu Y, Heinzmann M, Hamburg NM, Hamadé A, Jatoi NA, Karahan O, Karetova D, Karplus T, Klein-Weigel P, Kolossvary E, Kozak M, Lefkou E, Lessiani G, Liew A, Marcoccia A, Marshang P, Marakomichelakis G, Matuska J, Moraglia L, Pillon S, Poredos P, Prior M, Salvador DRK, Schlager O, Schernthaner G, Sieron A, Spaak J, Spyropoulos A, Sprynger M, Suput D, Stanek A, Stvrtinova V, Szuba A, Tafur A, Vandreden P, Vardas PE, Vasic D, Vikkula M, Wennberg P, Zhai Z, Scientific...
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, Antic D, Auad L, Banfic L, Bartolomew JR, Benczur B, Bernardo MB, Boccardo F, Cif Tags: Thromb Haemost Source Type: research

Novel Blood Coagulation Molecules: Skeletal Muscle Myosin and Cardiac Myosin.
Abstract Two striated muscle myosins, namely skeletal muscle myosin (SkM) and cardiac myosin (CM), may potentially contribute to physiologic mechanisms for regulation of thrombosis and hemostasis. Thrombin is generated from activation of prothrombin by the prothrombinase (IIase) complex comprising factor Xa, factor Va, and Ca++ ions located on surfaces where these factors are assembled. We discovered that SkM and CM, which are abundant motor proteins in skeletal and cardiac muscles, can provide a surface for thrombin generation by the prothrombinase complex without any apparent requirement for phosphatidylserine o...
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Deguchi H, Morla S, Griffin JH Tags: J Thromb Haemost Source Type: research

Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.
CONCLUSIONS: These findings suggest that the JAK2V617F mutation can alter vascular endothelial function to promote cardiovascular complications in MPNs. Therefore, targeting the MPN vasculature represents a promising new therapeutic strategy for patients with MPNs. PMID: 32920974 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 13, 2020 Category: Hematology Authors: Castiglione M, Jiang YP, Mazzeo C, Lee S, Chen JS, Kaushansky K, Yin W, Lin RZ, Zheng H, Zhan H Tags: J Thromb Haemost Source Type: research

Recombinant Thrombomodulin in Disseminated Intravascular Coagulation Associated with Stage IV Solid Tumors: A Nationwide Observational Study in Japan.
CONCLUSION:  Although we identified a possibly beneficial association between rTM administration and mortality in specific populations of patients with colorectal and gynecological cancer, no such association was found when considering the entire cohort of patients with DIC associated with stage IV solid tumors. PMID: 32906154 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 9, 2020 Category: Hematology Authors: Taniguchi K, Ohbe H, Yamakawa K, Matsui H, Fushimi K, Yasunaga H Tags: Thromb Haemost Source Type: research

Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
CONCLUSION:  Emicizumab enhanced thrombin generation at local sites and improved defective hemostasis in whole blood from PwHAs under high shear conditions. Simple concomitant use of BPAs with emicizumab did not mediate excessive thrombus formation and remains an option for hemostatic management of emicizumab-treated PwHAs with inhibitors. PMID: 32906155 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 9, 2020 Category: Hematology Authors: Yaoi H, Shida Y, Kitazawa T, Shima M, Nogami K Tags: Thromb Haemost Source Type: research

Antithrombotics from Frog Skin Secretions.
PMID: 32906156 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 9, 2020 Category: Hematology Authors: Ni H Tags: Thromb Haemost Source Type: research

Accuracy of contralateral Villalta score to assess for pre-existing chronic venous insufficiency in patients with unilateral deep vein thrombosis.
CONCLUSION: In our study of patients with a first unilateral proximal DVT, the proportion of patients with PTS who had a cl-VS>4 is modest. However, cl-VS appears to be stable over time. Its assessment could constitute a simple way of documenting preexisting PVI and help to classify patients as having PTS or not. PMID: 32898930 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 8, 2020 Category: Hematology Authors: Galanaud JP, Ducruet T, Kahn SR, SOX trial investigators group Tags: J Thromb Haemost Source Type: research

Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration.
DISCUSSION: Several trials evaluate different dose regimens of anticoagulant interventions in hospitalized patients with COVID-19. Since these trials compete for sites and study participants, a collaborative effort is needed to complete trials faster, conduct pooled analyses and bring effective interventions to patients more quickly. PMID: 32888372 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 5, 2020 Category: Hematology Authors: Tritschler T, Mathieu ME, Skeith L, Rodger M, Middeldorp S, Brighton T, Sandset PM, Kahn SR, Angus DC, Blondon M, Bonten MJ, Cattaneo M, Cushman M, Derde LPG, DeSancho MT, Diehl JL, Goligher E, Jilma B, Jüni P, Lawler PR, Marietta M, Marshall JC, McArthu Tags: J Thromb Haemost Source Type: research

Liver Transplantation as a Novel Strategy for Resolution of Congenital Afibrinogenemia in a Pediatric Patient.
Abstract Fibrinogen replacement therapy is a treatment mainstay for patients with afibrinogenemia and significant bleeding. A male infant with congenital afibrinogenemia and several spontaneous hemarthroses commenced cryoprecipitate prophylaxis but developed severe urticarial reactions. He transitioned to a human fibrinogen concentrate (HFC) (RiaSTAP®, CSL Behring; 70 mg/kg biweekly) but continued experiencing hemarthroses (estimated annualized bleeding rate [ABR]: 5-6) and severe anaphylactic reactions, despite pre- and post-infusion medications. Following switching to a new HFC (Fibryga®, Octapharma; 50 ...
Source: Thrombosis and Haemostasis - September 5, 2020 Category: Hematology Authors: Corrales-Medina FF, Miloh T, O'Farrell C, Andrews DM, Tekin A, De Angulo G Tags: J Thromb Haemost Source Type: research

A serine loop in tissue factor mediates substrate selectivity by the tissue factor - factor VIIa complex.
CONCLUSIONS: Our results provide new insights into how the TF-FVIIa complex actively selects between its major protein substrates, which is mediated by a TF serine loop. PMID: 32885882 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 4, 2020 Category: Hematology Authors: Birkle F, Morrissey JH Tags: J Thromb Haemost Source Type: research

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.
CONCLUSIONS: In GARFIELD-AF, despite similar characteristics, patients on anticoagulants were treated differently in NL and BE. Although the rate of major bleeding was 33% higher in NL, variations in bleeding, mortality and TE rates were not statistically significant. PMID: 32886853 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 4, 2020 Category: Hematology Authors: Seelig J, Hemels MEW, Xhaët O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman JR, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Piete Tags: J Thromb Haemost Source Type: research

The factor VIII treatment history of non-severe hemophilia A.
CONCLUSION: This study demonstrates that in non-severe hemophilia A, the age at first FVIII exposure increases with baseline FVIII:C and that major spontaneous bleeds rarely occur. PMID: 32877570 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 2, 2020 Category: Hematology Authors: Abdi A, Kloosterman FR, Eckhardt CL, Male C, Castaman G, Fischer K, Beckers EAM, Kruip MJHA, Peerlinck K, Mancuso ME, Santoro C, Charles HR, Platokouki H, van der Bom JG, Gouw SC, Fijnvandraat K, Hart DP, INSIGHT study group Tags: J Thromb Haemost Source Type: research

The Role of ROCK in Platelet-Monocyte Collaborative Induction of Thromboinflammation during Acute Coronary Syndrome.
CONCLUSION:  Through ROCK-activated cytoskeleton remodeling and P-selectin expression, platelets were recruited and interacted synergistically with high CCR2-expressing monocytes to induce thromboinflammation in atherothrombosis. PMID: 32877952 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 2, 2020 Category: Hematology Authors: Hsu LW, Chen PW, Chang WT, Lee WH, Liu PY Tags: Thromb Haemost Source Type: research

Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population Sample.
CONCLUSION:  In the Gutenberg Health Study population-based cohort, the highest percentage of total TFPI correlated with an increased mortality risk. While elevated TFPI may reflect endothelial cell activation, the associations between total TFPI activity and obesity and CAD, points to additional mechanistic interactions. PMID: 32877953 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 2, 2020 Category: Hematology Authors: van Paridon PCS, Panova-Noeva M, van Oerle R, Schulz A, Prochaska JH, Arnold N, Schmidtmann I, Beutel M, Pfeiffer N, Münzel T, Lackner KJ, Hackeng TM, Ten Cate H, Wild PS, Spronk HMH Tags: Thromb Haemost Source Type: research

Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study.
Abstract BACKGROUND:  There are acute settings where assessing the anticoagulant effect of direct oral anticoagulants (DOACs) can be useful. Due to variability among routine coagulation tests, there is an unmet need for an assay that detects DOAC effects within minutes in the laboratory or at the point of care. METHODS:  We developed a novel dielectric microsensor, termed ClotChip, and previously showed that the time to reach peak permittivity (T peak) is a sensitive parameter of coagulation function. We conducted a prospective, single-center, pilot study to determine its clinical utility at detecti...
Source: Thrombosis and Haemostasis - September 2, 2020 Category: Hematology Authors: Maji D, Opneja A, Suster MA, Bane KL, Wilson BM, Mohseni P, Stavrou EX Tags: Thromb Haemost Source Type: research

Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source.
Abstract BACKGROUND:  Atrial cardiopathy and likely pathogenic patent foramen ovale (PFO) are two potential embolic sources in patients with embolic stroke of undetermined source (ESUS). The relationship between these two mechanisms among ESUS patients remains unclear. METHODS:  Atrial cardiopathy was defined as increased left atrial diameter index (> 23 mm/m2) or left atrial volume index (> 34 mL/m2), or PR prolongation (≥ 200 ms), or presence of supraventricular extrasystoles in the electrocardiograms performed during hospitalization for the index stoke. The presence ...
Source: Thrombosis and Haemostasis - September 2, 2020 Category: Hematology Authors: Leventis IA, Sagris D, Strambo D, Perlepe K, Sirimarco G, Nannoni S, Korompoki E, Manios E, Makaritsis K, Vemmos K, Michel P, Ntaios G Tags: Thromb Haemost Source Type: research

Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study).
CONCLUSION:  This study showed that treatment-related decision making in cancer-associated VTE, assuming comparable effectiveness and safety of anticoagulant treatments, is predominantly driven by "route of administration," with patients strongly preferring oral administration. PMID: 32877956 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 2, 2020 Category: Hematology Authors: Picker N, Lee AY, Cohen AT, Maraveyas A, Beyer-Westendorf J, Mantovani LG, Abdelgawwad K, Fatoba S, Thate-Waschke IM, Bach M, Wilke T Tags: Thromb Haemost Source Type: research

Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients.
In conclusion, we have identified complement activation through the MBL pathway as a novel amplification mechanism that contributes to pathological thrombosis in critically ill COVID-19 patients. Pharmacological targeting of the MBL pathway could be a novel treatment option for thrombosis in COVID-19. Laboratory testing of MBL levels could be of value for identifying COVID-19 patients at risk for TE events. PMID: 32871607 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 1, 2020 Category: Hematology Authors: Eriksson O, Hultström M, Persson B, Lipcsey M, Ekdahl KN, Nilsson B, Frithiof R Tags: Thromb Haemost Source Type: research

Effect of myeloperoxidase on the anticoagulant activity of low-molecular-weight heparin and rivaroxaban in an in-vitro tumor model.
CONCLUSIONS: MPO release may partially attenuate the anticoagulant activity of trough levels of dalteparin and tinzaparin in the context of paraneoplastic leukocyte activation. However, this effect is likely not sufficient to explain the improved efficacy of rivaroxaban, and possibly other oral factor Xa inhibitors, in CAT treatment. PMID: 32865287 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 31, 2020 Category: Hematology Authors: Voigtlaender M, Beckmann L, Schulenkorf A, Sievers B, Rolling C, Bokemeyer C, Langer F Tags: J Thromb Haemost Source Type: research

First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura.
CONCLUSION: Hetrombopag was well tolerated and preliminary efficacious. Efficacy, safety and PK data suggested that 7.5 mg hetrombopag once daily was the anticipated therapeutic dose of hetrombopag in CITP patients and have been recommended to investigate in the later confirmatory clinical study of hetrombopag. PMID: 32865293 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 31, 2020 Category: Hematology Authors: Wang Z, Chen L, Zhang F, Lu H, Chen X, Wen A, Luo J, Hu Y, Wang Y, Niu T, Zheng L Tags: J Thromb Haemost Source Type: research

Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
CONCLUSIONS: A pronounced activation of the CPU system was observed during tMCAO in rats. Selective inhibition of CPU with AZD9684 was able to reduce fibrinogen deposition and brain edema, suggesting a reduction of MT but without a significant effect on final infarct volume. PMID: 32869423 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 31, 2020 Category: Hematology Authors: Mertens JC, Boisseau W, Leenaerts D, Di Meglio L, Loyau S, Lambeir AM, Ducroux C, Jandrot-Perrus M, Michel JB, Mazighi M, Hendriks D, Desilles JP Tags: J Thromb Haemost Source Type: research

External validation of the YEARS diagnostic algorithm for suspected pulmonary embolism.
Abstract BACKGROUND: Validated diagnostic algorithms are used to manage patients with suspected pulmonary embolism (PE). The recently published YEARS study proposed a simplified diagnostic strategy to reduce the use of computed tomography pulmonary angiography. OBJECTIVES: To externally validate this strategy in an independent cohort. METHODS: We analyzed data from three previous prospective cohort studies of outpatients with suspected PE. We retrospectively applied the YEARS algorithm. The three YEARS clinical criteria are: clinical signs of deep vein thrombosis, hemoptysis, and PE as the most likely di...
Source: Thrombosis and Haemostasis - August 31, 2020 Category: Hematology Authors: Eddy M, Robert-Ebadi H, Richardson L, Bellesini M, Verschuren F, Moumneh T, Meyer G, Righini M, Le Gal G Tags: J Thromb Haemost Source Type: research

Oral Administration of Fucosylated Chondroitin Sulfate Oligomers in Gastro-Resistant Microcapsules Exhibits a Safe Antithrombotic Activity.
Abstract Fucosylated chondroitin sulfate (FCS) polysaccharide isolated from sea cucumber has potent anticoagulant activity. Based on its resistance to the enzymes present in vertebrates, it may serve as an anticoagulant and shows antithrombotic effects when delivered through gastro-resistant (GR) tablets. However, due to the multiple plasma targets of FCS polysaccharide in the coagulation pathway, bleeding can occur after its oral administration. In the current study, we used FCS oligomers, in particular a mixture of oligosaccharides having 6 to 18 saccharide units, as the active ingredient in GR microcapsules for...
Source: Thrombosis and Haemostasis - August 30, 2020 Category: Hematology Authors: Yan L, Zhu M, Wang D, Tao W, Liu D, Zhang F, Linhardt RJ, Ye X, Chen S Tags: Thromb Haemost Source Type: research

Lessons Learnt from Recent Trials in Ischemic Heart Disease.
Abstract Four recently published randomized controlled trials have informed the care of patients with stable ischemic heart disease. The purpose of this clinical focus article is to offer a summary and critical appraisal of the recent evidence. We aim to aid clinicians in the translation of the trial evidence to patient care. PMID: 32862409 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 30, 2020 Category: Hematology Authors: Mandrola JM, Kaul S, Foy A Tags: Thromb Haemost Source Type: research

Direct Oral Anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center.
PMID: 32862410 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 30, 2020 Category: Hematology Authors: Bhoelan BS, Mulder R, Lukens MV, Meijer K Tags: Thromb Haemost Source Type: research

Staging Severity of COVID-19 according to Hemostatic Abnormalities (CAHA Score).
Abstract This is the first study to show a stepwise increase in venous thrombotic events according to COVID-19 coagulopathy (COVID-19-associated hemostatic abnormalities [CAHA]) staging and lung injuries assessed by chest computed tomography. Excess mortality and/or transfer to intensive care unit according to CAHA staging. PMID: 32862411 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 30, 2020 Category: Hematology Authors: Marchandot B, Trimaille A, Curtiaud A, Carmona A, Matsushita K, Sato C, Leonard-Lorant I, Sattler L, Grunebaum L, Ohana M, Ohlmann P, Jesel L, Morel O Tags: Thromb Haemost Source Type: research

Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study.
CONCLUSION:  These data indicated that obese or high BW patients generally achieve therapeutic FXa inhibitor concentrations. However, further investigations assessing clinical outcomes are required. PMID: 32862412 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 30, 2020 Category: Hematology Authors: Martin AC, Thomas W, Mahir Z, Crowley MP, Dowling T, Breen K, Collings V, Moore GW, MacDonald S, Hunt BJ, Cohen AT Tags: Thromb Haemost Source Type: research

Response to Maccio et al., "Multifactorial Pathogenesis of COVID-19-related Coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?"
Response to Maccio et al., "Multifactorial Pathogenesis of COVID-19-related Coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?" J Thromb Haemost. 2020 Aug 28;: Authors: Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J, Mo C, O'Gorman P, Yanik G, Palomo M, Diaz-Ricart M, Moraleda JM, DEFACOVID Study Group Abstract We read with interest the letter by Maccio et al., which postulates a role for defibrotide (DF) in the treatment of coagulation disorders observed in COVID-19 [1]. Their commentary effectively explores the contribution of ...
Source: Thrombosis and Haemostasis - August 28, 2020 Category: Hematology Authors: Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J, Mo C, O'Gorman P, Yanik G, Palomo M, Diaz-Ricart M, Moraleda JM, DEFACOVID Study Group Tags: J Thromb Haemost Source Type: research

Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater.
Response to "Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitation": don't throw the baby out with the bathwater. J Thromb Haemost. 2020 Aug 28;: Authors: Nougier C, Benoit R, Dargaud Y Abstract We appreciate the opportunity to respond to the letter from Dr Hardy and colleagues (1). The authors stress on the large variability observed between different anti-Xa kits available on the market, they contest our results of thrombin generation assay (TGA) in patients with COVID-19 receiving standard- or high-dose prophylaxis a...
Source: Thrombosis and Haemostasis - August 28, 2020 Category: Hematology Authors: Nougier C, Benoit R, Dargaud Y Tags: J Thromb Haemost Source Type: research

Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis.
ola R Abstract We thank Dr. Thachil for his interesting comment regarding our article (1). Indeed, we agree that the precise contribution of various risk factors to the development of venous thromboembolism (VTE) in COVID-19 patients remains to be fully elucidated. In this context, it is possible that also hypoxia, either prior or during hospitalisation, might have a role on the development of thrombosis. In our study, non ICU-subjects with deep vein thrombosis (DVT) more frequently required oxygen supplementation (100.0 % vs 83.7 %) and high flow nasal oxygen therapy or non-invasive ventilation (NIV) (60.0% vs 8....
Source: Thrombosis and Haemostasis - August 28, 2020 Category: Hematology Authors: Porfidia A, Santoliquido A, Cammá G, Porceddu E, Pola R Tags: J Thromb Haemost Source Type: research

Tranexamic acid in acute gastrointestinal bleeding - A cautionary tale.
PMID: 32856769 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - August 28, 2020 Category: Hematology Authors: Roberts LN Tags: J Thromb Haemost Source Type: research